Xeris Biopharma Holdings, Inc. (CIK: 0001867096) EDGAR, Information, Filings... CompaniesBIO.Com

Xeris Biopharma Holdings, Inc.

Mailing address
180 N. LASALLE STREET, SUITE 1600, CHICAGO, Delaware, 60601
Phone
844-445-5704
State location
Illinois
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
Filings
N/A

Xeris Biopharma Holdings, Inc. (CIK: 0001867096) is an American company incorporated in the state of Illinois. Head office is located at 180 N. LASALLE STREET, SUITE 1600, CHICAGO, Illinois, 60601. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Xeris Biopharma Holdings, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Fairley Ricki Louise	0001971350	Mar-27-2023	director
SHERMAN JEFFREY W	0001230482	Oct-05-2021	director
PERSKY MARLA	0001270354	Oct-05-2021	director
JOHNSON JOHN	0001410781	Oct-05-2021	director
Kong Garheng	0001435183	Oct-05-2021	director
Schmid John P.	0001478916	Oct-05-2021	director
Edick Paul R	0001531178	Oct-05-2021	director, officer: See Remarks
Shannon John Patrick Jr	0001553595	Oct-05-2021	officer: See Remarks
BORMANN-KENNEDY BARBARA-JEAN ANNE	0001635065	Oct-05-2021	director
Hecht Beth	0001652410	Oct-05-2021	officer: See Remarks
HALKUFF DAWN	0001743658	Oct-05-2021	director
JOHNSON KENNETH ERLAND	0001743774	Oct-05-2021	officer: See Remarks
PRESTRELSKI STEVEN	0001744027	Oct-05-2021	officer: Chief Scientific Officer
Pieper Steven	0001875714	Oct-05-2021	officer: Chief Financial Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Xeris Biopharma Holdings, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000141 ( Act) Size: 0 KB	Aug-15-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000138 ( Act) Size: 0 KB	Aug-13-2025
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001950047-25-005741 (33 Act) Size: 0 KB	Aug-13-2025	001-40880 251211623
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001950047-25-005670 (33 Act) Size: 0 KB	Aug-12-2025	001-40880 251207100
10-Q	Document	Quarterly report pursuant to sections 13 or 15(d) Acc-no: 0001867096-25-000136 (34 Act) Size: KB	Aug-07-2025	001-40880 251194938
8-K	Document	Current report filing Acc-no: 0001867096-25-000130 (34 Act) Size: KB	Aug-07-2025	001-40880 251191717
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000124 ( Act) Size: 0 KB	Aug-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000123 ( Act) Size: 0 KB	Aug-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000118 ( Act) Size: 0 KB	Jun-16-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000116 ( Act) Size: 0 KB	Jun-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000114 ( Act) Size: 0 KB	Jun-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000112 ( Act) Size: 0 KB	Jun-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000110 ( Act) Size: 0 KB	Jun-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000108 ( Act) Size: 0 KB	Jun-04-2025
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001867096-25-000106 ( Act) Size: 0 KB	Jun-04-2025
8-K	Document	Current report filing Acc-no: 0001867096-25-000104 (34 Act) Size: KB	Jun-04-2025	001-40880 251024097
8-K	Document	Current report filing Acc-no: 0001867096-25-000100 (34 Act) Size: KB	Jun-03-2025	001-40880 251017203
EFFECT	Document	Acc-no: 9999999995-25-001553 (33 Act) Size: KB	May-13-2025	333-285597 25942433
144	Document	Filing for proposed sale of securities under Rule 144 Acc-no: 0001972362-25-000422 (33 Act) Size: 0 KB	May-09-2025	001-40880 25931833
CORRESP	Document	A correspondence can be sent as a document with another submission type or can be sent as a separate submission. Acc-no: 0001867096-25-000091 ( Act) Size: KB	May-09-2025

Recent 20 filings. View all Xeris Biopharma Holdings, Inc. filings

Overall rating 5.0

Aug 22, 2022

Catherine

Thanks I look forward to using the product to improve my skin tone

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Xeris Biopharma Holdings, Inc. overview
Xeris Biopharma Holdings, Inc. job
Xeris Biopharma Holdings, Inc. stock
Xeris Biopharma Holdings, Inc. ownership
Xeris Biopharma Holdings, Inc. CEO
Xeris Biopharma Holdings, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.